Navarixin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Navarixin
Accession Number
DB11711
Description

Navarixin has been investigated for the treatment of Asthma.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 410.47
Monoisotopic: 410.184171945
Chemical Formula
C23H26N2O5
Synonyms
  • Navarixin anhydrous
External IDs
  • SCH-527123

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Product Ingredients
IngredientUNIICASInChI Key
Navarixin monohydrate7V3BY6G538862464-58-2OVPWPDFETBKAQQ-UNTBIKODSA-N

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as salicylamides. These are carboxamide derivatives of salicylic acid. Salicylic acid is the ortho-hydroxylated derivative of benzoic acid.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Salicylamides
Alternative Parents
Benzamides / Benzoyl derivatives / Secondary alkylarylamines / Aralkylamines / 1-hydroxy-4-unsubstituted benzenoids / Vinylogous amides / Vinylogous acids / Tertiary carboxylic acid amides / Heteroaromatic compounds / Furans
show 5 more
Substituents
1-hydroxy-4-unsubstituted benzenoid / Amine / Amino acid or derivatives / Aralkylamine / Aromatic heteromonocyclic compound / Benzamide / Benzoyl / Carboxamide group / Carboxylic acid derivative / Cyclic ketone
show 17 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
4GMU5HUX5I
CAS number
473727-83-2
InChI Key
IXBYSXNOKFHHDR-QGZVFWFLSA-N
InChI
InChI=1S/C23H26N2O5/c1-5-7-17(18-11-10-13(2)30-18)24-19-16(21(27)22(19)28)12-14-8-6-9-15(20(14)26)23(29)25(3)4/h6,8-11,17,24,26H,5,7,12H2,1-4H3/t17-/m1/s1
IUPAC Name
2-hydroxy-N,N-dimethyl-3-[(2-{[(1R)-1-(5-methylfuran-2-yl)butyl]amino}-3,4-dioxocyclobut-1-en-1-yl)methyl]benzamide
SMILES
CCC[C@@H](NC1=C(CC2=CC=CC(C(=O)N(C)C)=C2O)C(=O)C1=O)C1=CC=C(C)O1

References

General References
Not Available
PubChem Compound
71587743
PubChem Substance
347828076
ChemSpider
32702380

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Active Not RecruitingTreatmentCastration Resistant Prostate Cancer (CRPC) / Castration-Resistant Prostate Cancer (CRPC) / Microsatellite Stable Colorectal Cancer / Non-Small Cell Lung Carcinoma (NSCLC) / Tumors, Solid1
2CompletedTreatmentAsthma1
2CompletedTreatmentNeutrophilic Asthma1
2CompletedTreatmentPsoriasis1
2TerminatedTreatmentChronic Obstructive Pulmonary Disease (COPD)2
2WithdrawnTreatmentAsthma1
1TerminatedNot AvailableChronic Obstructive Pulmonary Disease (COPD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0386 mg/mLALOGPS
logP3.43ALOGPS
logP4.06ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)7.98ChemAxon
pKa (Strongest Basic)-1.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area99.85 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity114.86 m3·mol-1ChemAxon
Polarizability43.63 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on October 20, 2016 14:41 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates